Analysts have been eager to weigh in on the Healthcare sector with new ratings on HUTCHMED (HCM – Research Report) and PAVmed (PAVM – Research Report).
HUTCHMED (HCM)
In a report released today, Paul Choi from Goldman Sachs maintained a Hold rating on HUTCHMED. The company’s shares closed last Wednesday at $21.43, close to its 52-week high of $21.92.
According to TipRanks.com, Choi is a 4-star analyst with an average return of
Currently, the analyst consensus on HUTCHMED is a Moderate Buy with an average price target of $29.00.
See Insiders’ Hot Stocks on TipRanks >>
PAVmed (PAVM)
In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on PAVmed, with a price target of $9.00. The company’s shares closed last Wednesday at $1.98, close to its 52-week low of $1.60.
According to TipRanks.com, Vendetti has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
PAVmed has an analyst consensus of Strong Buy, with a price target consensus of $13.00, which is a 477.8% upside from current levels. In a report released today, Lake Street also reiterated a Buy rating on the stock with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on HCM:
- HUTCHMED Launches Innovative Cancer Treatment Trial
- HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
- HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
- Hutchmed initiates Phase 2/3 trial of Surufatinib and Camrelizumab combination
- Hutchmed Shareholders Approve All AGM Resolutions
